NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries

NEWPORT BEACH, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC” or the “Company”), today announced the initiation of Phase III of its AI Development Program (“AI Development Program”) with Yuva Biosciences, Inc. (“YuvaBio”) under the Development and License Agreement ("Agreement") between the parties. Phase III will advance AI-driven compound identification in Phase II of the AI Development Program to experimental validation, marking a significant step towards advancing NorthStrive Biosciences’ pipeline of therapies addressing obesity and related metabolic conditions.